Predicting the sites of metastases from lung cancer using molecular biologic markers
- 1 October 2001
- journal article
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 72 (4) , 1144-1148
- https://doi.org/10.1016/s0003-4975(01)02979-4
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Molecular biologic substaging of stage I lung cancer according to gender and histologyThe Annals of Thoracic Surgery, 2000
- A biologic risk model for stage I lung cancer: Immunohistochemical analysis of 408 patients with the use of ten molecular markersThe Journal of Thoracic and Cardiovascular Surgery, 1999
- Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications.Journal of Clinical Oncology, 1998
- Revisions in the International System for Staging Lung CancerChest, 1997
- Angiogenesis and molecular biologic substaging in patients with stage I non—small cell lung cancerThe Annals of Thoracic Surgery, 1996
- Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trialsBMJ, 1995
- Stage I nonsmall cell lung cancer. A multivariate analysis of treatment methods and patterns of recurrenceCancer, 1995
- Survival in early-stage non-small cell lung cancerThe Annals of Thoracic Surgery, 1995
- Is T factor of the TNM staging system a predominant prognostic factor in pathologic stage I non-small-cell lung cancer?The Journal of Thoracic and Cardiovascular Surgery, 1993
- Histopathologic prognostic factors in adenocarcinomas of the peripheral lung less than 2 CM in diameterCancer, 1988